Verastem Oncology's New Cancer Treatment Gets FDA Priority Review

Dow Jones

Dec 31, 2024

By Kailyn Rhone

Verastem Oncology said its treatment for recurrent low-grade serous ovarian cancer has been given priority review by the Food and Drug Administration.

The new drug application for the treatment in adults combines two drugs, avutometinib and defactinib.

The FDA's decision is expected by June 30, 2025. If approved, it would be the first treatment specifically for this type of cancer, the company said.

"We're taking an important step forward in addressing a condition that has long been overlooked," said Dan Paterson, president and chief executive officer of Verastem Oncology, "We look forward to working with the FDA during its review process and preparing for a commercial launch in mid-2025."

Shares soared 21% after hours to $4.46. For the year, shares are down by more than 50 percent.

Write to Kailyn Rhone at kailyn.rhone@wsj.com

(END) Dow Jones Newswires

December 30, 2024 17:20 ET (22:20 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2495501328"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2495501328\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2495501328?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-31 06:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2495501328","market":"hk","top_or_hot":-1,"title":"Verastem Oncology's New Cancer Treatment Gets FDA Priority Review","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kailyn Rhone \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Oncology said its treatment for recurrent low-grade serous ovarian cancer has been given priority review by the Food and Drug Administration. \n</p>\n<p>\n  The new drug application for the treatment in adults combines two drugs, avutometinib and defactinib. \n</p>\n<p>\n  The FDA's decision is expected by June 30, 2025. If approved, it would be the first treatment specifically for this type of cancer, the company said. \n</p>\n<p>\n  \"We're taking an important step forward in addressing a condition that has long been overlooked,\" said Dan Paterson, president and chief executive officer of Verastem Oncology, \"We look forward to working with the FDA during its review process and preparing for a commercial launch in mid-2025.\" \n</p>\n<p>\n  Shares soared 21% after hours to $4.46. For the year, shares are down by more than 50 percent. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kailyn Rhone at kailyn.rhone@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 30, 2024 17:20 ET (22:20 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem Oncology's New Cancer Treatment Gets FDA Priority Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem Oncology's New Cancer Treatment Gets FDA Priority Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-31 06:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kailyn Rhone \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Oncology said its treatment for recurrent low-grade serous ovarian cancer has been given priority review by the Food and Drug Administration. \n</p>\n<p>\n  The new drug application for the treatment in adults combines two drugs, avutometinib and defactinib. \n</p>\n<p>\n  The FDA's decision is expected by June 30, 2025. If approved, it would be the first treatment specifically for this type of cancer, the company said. \n</p>\n<p>\n  \"We're taking an important step forward in addressing a condition that has long been overlooked,\" said Dan Paterson, president and chief executive officer of Verastem Oncology, \"We look forward to working with the FDA during its review process and preparing for a commercial launch in mid-2025.\" \n</p>\n<p>\n  Shares soared 21% after hours to $4.46. For the year, shares are down by more than 50 percent. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kailyn Rhone at kailyn.rhone@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 30, 2024 17:20 ET (22:20 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VSTM","symbol_name":"Verastem","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2495501328","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2495501328","pubTimestamp":1735597200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Verastem Oncology said its treatment for recurrent low-grade serous ovarian cancer has been given priority review by the Food and Drug Administration.The new drug application for the treatment in adults combines two drugs, avutometinib and defactinib.The FDA's decision is expected by June 30, 2025. If approved, it would be the first treatment specifically for this type of cancer, the company said.\"We're taking an important step forward in addressing a condition that has long been overlooked,\" said Dan Paterson, president and chief executive officer of Verastem Oncology, \"We look forward to working with the FDA during its review process and preparing for a commercial launch in mid-2025.\". Shares soared 21% after hours to $4.46. For the year, shares are down by more than 50 percent.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VSTM":"Verastem","BK4139":"生物科技"},"translate_title":"Verastem Oncology癌症新疗法获得FDA优先审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":1},"content_text":"By Kailyn Rhone \n\n\n \n\n\nVerastem Oncology said its treatment for recurrent low-grade serous ovarian cancer has been given priority review by the Food and Drug Administration. \n\n\n  The new drug application for the treatment in adults combines two drugs, avutometinib and defactinib. \n\n\n  The FDA's decision is expected by June 30, 2025. If approved, it would be the first treatment specifically for this type of cancer, the company said. \n\n\n  \"We're taking an important step forward in addressing a condition that has long been overlooked,\" said Dan Paterson, president and chief executive officer of Verastem Oncology, \"We look forward to working with the FDA during its review process and preparing for a commercial launch in mid-2025.\" \n\n\n  Shares soared 21% after hours to $4.46. For the year, shares are down by more than 50 percent. \n\n\n \n\n\n  Write to Kailyn Rhone at kailyn.rhone@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 30, 2024 17:20 ET (22:20 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}